Results 161 to 170 of about 38,126 (252)

APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract BACKGROUND Apolipoprotein E (APOE) alleles are well‐established genetic risk factors for Alzheimer's disease (AD), but their effects on AD biomarkers (amyloid beta [Aβ]42/40, phosphorylated tau [p‐tau]181, neurofilament light chain [NfL], and glial fibrillary acidic protein [GFAP]) may vary across populations due to ancestry‐, age‐, and sex ...
Caitlin Cheung   +18 more
wiley   +1 more source

Cognitive screening biases in a secondary prevention Alzheimer's disease clinical trial

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) prevention trials have multiple steps to identify cognitively unimpaired individuals with AD biomarker evidence. Cognitive/functional screening tests may be biased in ethnoracial minorities, impacting trial eligibility.
Isha Sai   +7 more
wiley   +1 more source

Behavioral Phenotype Associations With Resting State EEG Signal Complexity and Power Spectral Density in Fragile X Syndrome

open access: yesAutism Research, Volume 19, Issue 3, March 2026.
ABSTRACT Fragile X Syndrome (FXS), an X‐linked genetic condition, is associated with a wide range of phenotypic manifestations, namely intellectual disability (ID), autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and atypical behaviors.
Mélodie Proteau‐Lemieux   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy